Abstract
Canavan disease (CD), a rare recessive autosomal genetic disorder, is characterized by early onset and a progressive spongy degeneration of the brain involving loss of the axon’s myelin sheath. After a relatively normal birth, homozygous individuals generally develop clinical symptoms within months, and usually die within several years of the onset of the disease. A biochemical defect associated with this disease results in reduced activity of the enzymeN-acetyl-l-aspartate amidohydrolase (aspartoacylase) and affected individuals have less ability to hydrolyzeN-acetyl-l-aspartate (NAA) in brain and other tissues. As a result of aspartoacylase deficiency, NAA builds up in extracellular fluids (ECF) and is excreted in urine. From an analysis of the NAA biochemical cycle in various tissues of many vertebrate species, evidence is presented that there may be two distinct NAA circulation patterns related to aspartoacylase activity. These include near-field circulations in the brain and the eye, and a far-field systemic circulation involving the liver and kidney, the purpose of which in each case is apparently to regenerate aspartate (Asp) in order for it to be recycled into NAA as part of the still unknown function of the NAA cycle. Based on the authors’ analysis, they have also identified several metabolic outcomes of the genetic biochemical aspartoacylase lesion. First, there is a daily induced Asp deficit in the central nervous system (CNS) that is at least six times the static level of available free Asp. Second, there is up to a 50-fold drop in the intercompartmental NAA gradient, and third, the ability of the brain to perform its normal intercompartmental cycling of NAA to Asp is terminated, and as a result, the only remaining long-term source of Asp for NAA synthesis is via nutritional supplementation of Asp or its metabolic precursors. Finally, the authors identify a potential maternal-fetal interaction that may be responsible for observed normal fetal development in utero, and that provides a rationale for, and suggests how, CD might respond to far-field nutritional, transplantation, or genetic engineering techniques to alter the course of the disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adachi M. and Volk B. W. (1968) Protracted form of spongy degeneration of the central nervous system (van Bogaert and Bertrand type).Neurology 18, 1084–1092.
Afanas’ev I., Suslova T. B., Cheremisina Z. P., Abramova N. E., and Korkina L. G. (1995) Study of antioxidant properties of metal aspartates.Analyst 120, 859–862.
Baslow M. H. (1997) A review of phylogenetic and metabolic relationships between the acylamino acids, N-acetyl-L-aspartic acid and N-acetyl-L-histidine in the vertebrate nervous system.J. Neurochem. 68, 1335–1344.
Baslow M. H. and Lenney J. F. (1967) a-N-Acetylhistidine amido-hydrolase activity from tuna fish brain: inhibition by phenothiazines.Seventh Int. Cong. Biochem. 5, 1014.
Baslow M. H. and Nigrelli R. F. (1961) Muscle acetylcholinesterase as an index of general activity in fishes.Copeia 1, 8–11.
Baslow M. H. and Nigrelli R. F. (1964) The effect of thermal acclimation on brain cholinesterase activity of the killifish, Fundulus heteroclitus.Zoologica 49(1), 41–51.
Baslow M. H. and Yamada S. (1997a) Identification of N-acetylaspartate in the lens of the vertebrate eye: a new model for the investigation of the function of N-acetylated amino acids in vertebrates.Exp. Eye Res. 64(2), 283–286.
Baslow M. H. and Yamada S. (1997b) Distribution of N-acetyl-L-histidine and N-acetyl-L-aspartate in the vertebrate eye.J. Neurochem. 69 (Suppl.), 5175D.
Bennett M. J., Gibson K. M., Sherwood W. G., Divry P., Rolland M. O., Elpeleg O. N., Rinaldo P., and Jakobs C. (1993) Reliable prenatal diagnosis of Canavan disease (aspartoacylase deficiency): comparison and enzymatic and metabolite analysis.J. Inher. Met. Dis. 16, 831–836.
Berlinguet L. and Laliberte M. (1966) Metabolism of N-acetyl-L-aspartic acid in mice.Can. J. Biochem. 44, 783–789.
Birken D. L. and Oldendorf W. H. (1989) N-Acetyl-L-aspartic acid: a literature review of a compound prominent in H-NMR spectroscopic studies of brain.Neurosci. Biobehav. Rev. 13, 23–31.
Boehme D. H. and Marks N. (1981) Protracted form of Canavan’s disease: casehistory and protein kinase activity of membrane fractions.Acta Neuropathol. 55, 221–225.
Bremer H. J., Duran M., Kamerling J. P., Przyrembel H., and Wadman S. K. (1981) Disturbances of amino acid metabolism: clinical chemistry and diagnosis. Urban and Schwarzenberg, Baltimore, MD, p. 536.
Buniatian H. C. H., Hovhannissian V. S., and Aprikian G. V. (1965) The participation of N-acetyl-L-aspartic acid in brain metabolism.J. Neurochem. 12, 695–703.
Burns S. P., Chalmers R. A., West R. J., and Iles R. A. (1992) Measurement of human brain aspartate N-acetyl transferase flux in vivo.Biochem. Soc. Trans. 20, 107S.
Canavan M. M. (1931) Schilders encephalitis periaxialis diffusa. Report of a case in a child aged sixteen and one-half months.Arch. Neurol. Psychiat. 25, 299–308.
Christensen H. N. (1990) Role of amino acid transport and countertransport in nutrition and metabolism.Physiol. Rev. 70, 43–77.
D’Adamo A. F. Jr., Smith J. C., and Woiler C. (1973) The occurrence of N-acetylaspartate amidohydrolase (aminoacylase II) in the developing rat.J. Neurochem. 20, 1275–1278.
During M. (1996) Gene therapy in New Zealand (letter).Science 272, 467.
Elpeleg O. N., Shaag A., Anikster Y., and Jakobs C. (1994) Prenatal detection of Canavan disease (aspartoacylase deficiency) by DNA analysis.J. Inher. Met. Dis. 17, 664–666.
Ferrari M. D., Odink J., Bos K. D., Malessy M. J. A., and Bruyn G. W. (1990) Neuroexcitatory plasma amino acids are elevated in migraine.Neurology 40, 1582–1586.
Ford F. R. (1960)Diseases of the Nervous System in Infancy, Childhood and Adolescence. Charles C. Thomas, Pub., Springfield, IL, p. 1548.
Goldstein F. B. (1976) Amidohydrolases of brain; enzymatic hydrolysis of N-acetyl-L-aspartate and other N-acyl-L-amino acids.J. Neurochem. 26, 45–49.
Kaul R., Casanova J., Johnson A. B., Tang P., and Matalon R. (1991) Purification, characterization, and localization of aspartoacylase from bovine brain.J. Neurochem. 56, 129–135.
Kaul R., Gao G. P., Balamurugan K., and Matalon R. (1993) Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.Nature Gen. 5, 118–123.
Kaul R., Gao G. P., Aloya M., Balamurugan K., Petrosky A., Michals K., and Matalon R. (1994a) Canavan disease: mutations among Jewish and non-Jewish patients.Am. J. Hum. Gen. 55, 34–41.
Kaul R., Balamurugan K., Gao G. P., and Matalon R. (1994b) Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution.Genomics 21, 364–370.
Kaul R., Gao G. P., Matalon R., Aloya M., Su Q., Jin M., Johnson A. B., Schutgens R. B., and Clarke J. T. (1996) Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease.Am. J. Hum. Gen. 59, 95–102.
Kelley R. I. (1993) Prenatal detection of Canavan disease by measurement of N-acetyl-L-aspartate in amniotic fluid.J. Inher. Metab. Dis. 16, 918, 919.
Kish S. J., Robitaille Y., el-Awar M., Gilbert J., Deck J., Chang L. J., and Schut L. (1991) Brain amino acid reductions in one family with chromosome 6p-linked dominantly inherited olivopontocerebellar atrophy.Ann. Neurol. 30, 780–784.
Kvittingen E. A., Guldal G., Borsting S., Skalpe I. O., Stokke O., and Jellum E. (1986) N-acetylaspartic aciduria in a child with a progressive cerebral atrophy.Clin. Chim. Acta 158, 217–227.
Levine R. J. (1996) Canavan gene therapy protocol (letter)Science 272, 1085.
Matalon R., Michals K., Sebasta D., Deanching M., Gashkoff P., and Casanova J. (1988) Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease.Am. J. Med. Genet. 29, 463–471.
Matalon R., Kaul R., Casanova J., Michals K., Johnson A., Rapin I., Gashkoff P., and Deanching M. (1989) Aspartoacylase deficiency: the enzyme defect in Canavan disease.J. Inher. Metab. Dis. 12, 329–331.
Matalon R., Kaul R., and Michals K. (1993) Canavan disease: biochemical and molecular studies.J. Inher. Met. Dis. 16, 744–752.
Matalon R., Michals K., and Kaul R. (1995) Canavan disease: from spongy degeneration to molecular analysis.J. Pediatr. 127, 511–517.
Oldendorf W. H. (1971) Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection.Am. J. Physiol. 221, 1629–1639.
Pevzner L. Z. (1979)Functional Biochemistry of the Neuroglia (Tiplady B., ed.), Plenum, New York, p. 306.
Reddy D. V. N. (1967) Distribution of free amino acids and related compounds in ocular fluids, lens and plasma of various mammalian species.Invest. Opthalmol. 6, 478–483.
Reilmann R., Rolf L. H., and Lange H. W. (1994) Huntington’s disease: the neuroexcitatoxin aspartate is increased in platelets and decreased in plasma.J. Neurol. Sci. 127, 48–53.
Riikonen R. S., Kero P. O., and Simell O. G. (1992) Excitatory amino acids in cerebrospinal fluid in neonatal asphyxia.Pediatr. Neurol. 8, 37–40.
Sager T. N., Fink-Jensen A., and Hansen A. J. (1997) Transient elevation of interstitial N-acetylaspartate in reversible global brain ischemia.J. Neurochem. 68, 675–682.
Sandberg M., Butcher S. P., and Hagberg H. (1986) Extracellular overflow of neuroactive amino acids during severe insulin-induced hypoglycemia: in vivo dialysis of the rat hippocampus.J. Neurochem. 47, 178–184.
Scriver C. R. and Rosenberg L. E. (1973) Amino acid metabolism and its disorders, inMajor Problems in Clinical Pediatrics, vol. X (Schaffer A. L., ed.), Saunders, Philadelphia, PA, p. 491.
Shaag A., Anikster Y., Christensen E., Glustein J. Z., Fois A., Michelakakis H., Nigro F., Pronicka E., Ribes A., Zabot M. T., et al. (1995) The molecular basis of Canavan (aspartoacylase deficiency) disease in European non-Jewish patients.Am. J. Hum. Gen. 57, 572–580.
Swahn C. G. (1990) Determination of N-acetylaspartic acid in human cerebrospinal fluid by gas chromatography-mass spectrometry.J. Neurochem. 54, 1584–1588.
Tallan H. H. (1957) Studies on the distribution of N-acetyl-L-aspartic acid in brain.J. Biol. Chem. 224, 41–45.
Tallan H. H., Moore S., and Stein W. H. (1954) Studies on the free amino acids and related compounds in the tissues of the cat.J. Biol. Chem. 211, 927–939.
Truckenmiller M. E., Namboodiri M. A. A., Browstein M. J., and Neale J. H. (1985) N-Acetylation of L-aspartate in the nervous system: differential distribution of a specific enzyme.J. Neurochem. 45, 1658–1662.
Urenjak J., Williams S. R., Gadian D. G., and Noble M. (1992) Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro.J. Neurochem. 59, 55–61.
Yamada S., Tanaka Y., Sameshima M., and Furuichi M. (1992) Occurrence of N-acetylhistidine in the muscle and deacetylation by several tissues of Nile tilapia (Oreochromis niloticus).Comp. Biochem. Physiol. [B]103, 579–583.
Yamada S., Tanaka Y., Sameshima M., and Furuichi M. (1993) Properties of N-acetylhistidine deacetylase in brain of trout Oncorhynchus mykiss.Comp. Biochem. Physiol. [B]106, 309–315.
Yamada S., Tanaka Y., Sameshima M., and Furiuchi M. (1994) Effects of starvation and feeding on tissue N-acetylhistidine levels in Nile tilapia Oreochromis niloticus.Comp. Biochem. Physiol. [A]109, 277–283.
Yamada S., Tanaka Y., and Furuichi M. (1995) Partial purification and characterization of histidine acetyltransferase in brain of Nile tilapia (Oreochromis niloticus).Biochim. Biophys. Acta 1245, 239–247.
Winick M. (1976)Malnutrition and Brain Development. Oxford University Press, New York, p. 169.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baslow, M.H., Resnik, T.R. Canavan disease. J Mol Neurosci 9, 109–125 (1997). https://doi.org/10.1007/BF02736855
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02736855